# 3SBio

Source: https://onco.cc/companies/3sbio/  
OnCo record `3sbio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

3SBio is a Shenyang biologics company whose HER2 antibody inetetamab was approved in China in 2020 for HER2-positive metastatic breast cancer.

## Summary

3SBio, listed in Hong Kong, is one of China's largest biologics makers, with a long-standing business in recombinant proteins (erythropoietin, thrombopoietin). In oncology its Fc-engineered HER2 antibody inetetamab (Cipterbin) was approved by the NMPA in June 2020 with vinorelbine for HER2-positive metastatic breast cancer. A 2025 licence of its PD-1 and VEGF bispecific antibody to Pfizer brought the company global attention.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Shenyang Sunshine Pharmaceutical; Sansheng Pharmaceutical
- Tags: ctgov-sponsor; china
- HQ: Shenyang, China
- Type: biotech
- Website: https://www.3sbio.com

## Sources

- Official website: https://www.3sbio.com

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Inetetamab](https://onco.cc/drugs/inetetamab/), [SSGJ-612](https://onco.cc/drugs/ssgj-612/), [SSGJ-705](https://onco.cc/drugs/ssgj-705/), [SSGJ-706](https://onco.cc/drugs/ssgj-706/)
- trials: [A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers](https://onco.cc/trials/nct07233850/), [A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients](https://onco.cc/trials/nct07171606/), [Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain](https://onco.cc/trials/nct07008703/), [SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors](https://onco.cc/trials/nct07022002/), [SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors](https://onco.cc/trials/nct07646626/), [SSGJ-707 in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06980272/)

---
JSON: https://onco.cc/api/v1/entities/3sbio.json